{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:38:58Z","timestamp":1787564338808,"version":"build-2736575974"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2019-12370456"],"award-info":[{"award-number":["RF-2019-12370456"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["5x1000 funds 2015"],"award-info":[{"award-number":["5x1000 funds 2015"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MUR","award":["5x1000 funds 2019"],"award-info":[{"award-number":["5x1000 funds 2019"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Peritoneal metastases from colorectal cancer (CRCPM) are related to poor prognosis. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been reported to improve survival, but peritoneal recurrence rates are still high and there is no consensus on the drug of choice for HIPEC. The aim of this study was to use patient derived organoids (PDO) to build a relevant CRCPM model to improve HIPEC efficacy in a comprehensive bench-to-bedside strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Oxaliplatin (L-OHP), cisplatin (CDDP), mitomycin-c (MMC) and doxorubicin (DOX) were used to mimic HIPEC on twelve PDO lines derived from twelve CRCPM patients, using clinically relevant concentrations. After chemotherapeutic interventions, cell viability was assessed with a luminescent assay, and the obtained dose\u2013response curves were used to determine the half-maximal inhibitory concentrations. Also, induction of apoptosis by different HIPEC interventions on PDOs was studied by evaluating CASPASE3 cleavage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Response to drug treatments varied considerably among PDOs. The two schemes with better response at clinically relevant concentrations included MMC alone or combined with CDDP. L-OHP showed relative efficacy only when administered at low concentrations over a long perfusion period. PDOs showed that the short course\/high dose L-OHP scheme did not appear to be an effective choice for HIPEC in CRCPM. HIPEC administered under hyperthermia conditions enhanced the effect of chemotherapy drugs against cancer cells, affecting PDO viability and apoptosis. Finally, PDO co-cultured with cancer-associated fibroblast impacted HIPEC treatments by increasing PDO viability and reducing CASPASES activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study suggests that PDOs could be a reliable in vitro model to evaluate HIPEC schemes at individual-patient level and to develop more effective treatment strategies for CRCPM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-024-03052-5","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:01:47Z","timestamp":1714608107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Colorectal carcinoma peritoneal metastases-derived organoids: results and perspective of a model for tailoring hyperthermic intraperitoneal chemotherapy from bench-to-bedside"],"prefix":"10.1186","volume":"43","author":[{"given":"Luca","family":"Varinelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Battistessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Guaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Zanutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Illescas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina J.","family":"Lorenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pisati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Kusamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Sabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Milione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Perbellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Noci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Paolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Galassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Cavalleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Deraco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Gariboldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Baratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"issue":"5","key":"3052_CR1","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1245\/s10434-021-09587-7","volume":"28","author":"M Guaglio","year":"2021","unstructured":"Guaglio M, Baratti D, Kusamura S, Reis ACV, Montenovo M, Bartolini V, et al. Impact of Previous Gynecologic Surgical Procedures on Outcomes of Non-Gynecologic Peritoneal Malignancies Mimicking Ovarian Cancer: Less Is More? Ann Surg Oncol. 2021;28(5):2899\u2013908.","journal-title":"Ann Surg Oncol"},{"key":"3052_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.critrevonc.2016.01.017","volume":"100","author":"D Baratti","year":"2016","unstructured":"Baratti D, Kusamura S, Pietrantonio F, Guaglio M, Niger M, Deraco M, et al. Progress in treatments for colorectal cancer peritoneal metastases during the years 2010\u20132015. A systematic review. Crit Rev Oncol Hematol. 2016;100:209\u201322.","journal-title":"Crit Rev Oncol Hematol."},{"key":"3052_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosello S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10\u201332.","journal-title":"Ann Oncol"},{"issue":"2","key":"3052_CR4","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, Go\u00e9r\u00e9 D, Ghouti L, Pocard M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cyoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366.","journal-title":"Lancet Oncol"},{"issue":"7","key":"3052_CR5","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.3390\/cancers15071926","volume":"15","author":"K Ukegjini","year":"2023","unstructured":"Ukegjini K, Guidi M, Lehmann K, Suvweg K, Putora PM, Cihoric N, et al. Current research and development in hyperthermic intraperitoneal chemotherapy (HIPEC) a cross-sectional analysis of clinical trials registered on ClinicalTrials.gov. Cancers (Basel). 2023;15(7):1926.","journal-title":"Cancers (Basel)."},{"issue":"6","key":"3052_CR6","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","volume":"18","author":"XJ Yang","year":"2011","unstructured":"Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575\u201381.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"3052_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ Van Driel","year":"2018","unstructured":"Van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230\u201340.","journal-title":"N Engl J Med"},{"key":"3052_CR8","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamasurg.2023.0662","volume":"158","author":"A Arjona-Sanchez","year":"2023","unstructured":"Arjona-Sanchez A, Espinosa-Redondo E, Guti\u00e9rrez-Calvo A, Segura-Sampedro JJ, P\u00e9rez-Viejo E, Concepci\u00f2n-Martin V, et al. Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colon cancer: A phase III randomized clinical trial. JAMA Surg. 2023;158:683\u201391.","journal-title":"JAMA Surg"},{"issue":"3","key":"3052_CR9","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ejso.2018.10.542","volume":"45","author":"W Celeen","year":"2019","unstructured":"Celeen W. HIPEC with oxaliplatin for colorectal peritoneal metastasis: The end of the road? Eur J Surg Oncol. 2019;45(3):400\u20132.","journal-title":"Eur J Surg Oncol"},{"issue":"1\u20132","key":"3052_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, et al. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell. 2018;172(1\u20132):373\u201386.e10.","journal-title":"Cell."},{"issue":"2","key":"3052_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","volume":"173","author":"SH Lee","year":"2018","unstructured":"Lee SH, Hu W, Matulay JT, Silva MV, Owczarek TB, Kim K, et al. Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. Cell. 2018;173(2):515\u201328.e17.","journal-title":"Cell"},{"issue":"11","key":"3052_CR12","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-18-0474","volume":"8","author":"SJ Hill","year":"2018","unstructured":"Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ Jr, et al. Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discov. 2018;8(11):1404\u201321.","journal-title":"Cancer Discov"},{"issue":"9","key":"3052_CR13","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","volume":"8","author":"H Tiriac","year":"2018","unstructured":"Tiriac H, Belleau P, Engle DD, Plenker D, Desch\u00eanes A, Somerville TDD, et al. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov. 2018;8(9):1112\u201329.","journal-title":"Cancer Discov"},{"issue":"6378","key":"3052_CR14","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fern\u00e1ndez-Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359(6378):920\u20136.","journal-title":"Science"},{"issue":"5","key":"3052_CR15","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/2159-8290.CD-16-1154","volume":"7","author":"C Pauli","year":"2017","unstructured":"Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, et al. Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer Discov. 2017;7(5):462\u201377.","journal-title":"Cancer Discov"},{"issue":"6444","key":"3052_CR16","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1126\/science.aaw6985","volume":"364","author":"D Tuveson","year":"2018","unstructured":"Tuveson D, Clevers H. Cancer modeling meets human organoid technology. Science. 2018;364(6444):952\u20135.","journal-title":"Science"},{"issue":"12","key":"3052_CR17","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41568-019-0209-6","volume":"19","author":"Y Shaked","year":"2019","unstructured":"Shaked Y. The pro-tumorigenic host response to cancer therapies. Nat Rev Cancer. 2019;19(12):667\u201385.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"3052_CR18","doi-asserted-by":"publisher","first-page":"mjac064","DOI":"10.1093\/jmcb\/mjac064","volume":"14","author":"L Varinelli","year":"2023","unstructured":"Varinelli L, Guaglio M, Brich S, Zanutto S, Belfiore A, Zanardi F, et al. Decellularized Normal and Tumor Extracellular Matrix as Scaffold for Cancer Organoid Cultures of Colorectal Peritoneal Metastases. J Moll Cell Biol. 2023;14(11):mjac064.","journal-title":"J Moll Cell Biol."},{"issue":"6","key":"3052_CR19","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.stem.2016.04.003","volume":"18","author":"M Fujii","year":"2016","unstructured":"Fujii M, Shimokawa M, Date S, Takano A, Matano M, Nanki K, et al. A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis. Cell Stem Cell. 2016;18(6):827\u201338.","journal-title":"Cell Stem Cell"},{"issue":"540","key":"3052_CR20","doi-asserted-by":"publisher","first-page":"215737","DOI":"10.1016\/j.canlet.2022.215737","volume":"1","author":"N Walerskirchen","year":"2022","unstructured":"Walerskirchen N, M\u00fcller C, Ramos C, Zeindl S, Stang S, Herzog D, et al. Metastatic colorectal carcinoma-associated fibroblast have immunosuppressive properties related to increased IGFBP2 expression. Cancer Lett. 2022;1(540):215737.","journal-title":"Cancer Lett"},{"issue":"14","key":"3052_CR21","doi-asserted-by":"publisher","first-page":"1053920","DOI":"10.3389\/fimmu.2023.1053920","volume":"16","author":"E Strating","year":"2023","unstructured":"Strating E, Verhagen MP, Wensink E, D\u00fcnnebach E, Wijler L, Aranguren I, et al. Co-cultures of colon cancer cells and cancer-associated fibroblasts recapitulate the aggressive features of mesenchymal-like colon cancer. Front Immunol. 2023;16(14):1053920.","journal-title":"Front Immunol"},{"issue":"1","key":"3052_CR22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1245\/s10434-019-07935-2","volume":"27","author":"D Baratti","year":"2020","unstructured":"Baratti D, Kusamura S, Azmi N, Guaglio M, Montenovo M, Deraco M. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS). Ann Surg Oncol. 2020;27(1):98\u2013106.","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"3052_CR23","doi-asserted-by":"publisher","first-page":"9098","DOI":"10.1245\/s10434-021-10193-w","volume":"28","author":"A Bhatt","year":"2021","unstructured":"Bhatt A, de Hingh I, Van Der Speeten K, Hubner M, Deraco M, Bakrin N, et al. HIPEC Methodology and Regimens: The Need for an Expert Consensus. Ann Surg Oncol. 2021;28(13):9098\u2013113.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"3052_CR24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ejso.2017.10.216","volume":"44","author":"WJ van Eden","year":"2018","unstructured":"van Eden WJ, Kok NFM, Woensdregt K, Huitema ADR, Boot H, Aalbers AGJ. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2018;44(2):220\u20137.","journal-title":"Eur J Surg Oncol"},{"issue":"13","key":"3052_CR25","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1245\/s10434-013-3145-9","volume":"20","author":"AMJ Kuijpers","year":"2013","unstructured":"Kuijpers AMJ, Mirck B, Aalbers AGJ. Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol. 2013;20(13):4224\u201330.","journal-title":"Ann Surg Oncol"},{"key":"3052_CR26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18:407\u201318.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"3052_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrd1635","volume":"4","author":"A Kamb","year":"2005","unstructured":"Kamb A. What\u2019s wrong with our cancer models? Nat Rev Drug Discov. 2005;4(2):161\u20135.","journal-title":"Nat Rev Drug Discov"},{"key":"3052_CR28","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/bjs.11206","volume":"106","author":"I Ubink","year":"2019","unstructured":"Ubink I, Bolhaqueiro ACF, Elias SG, Raats DAE, Constantinides A, Peters NA, et al. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy. Br J Surg. 2019;106:1404\u201314.","journal-title":"Br J Surg"},{"issue":"13","key":"3052_CR29","doi-asserted-by":"publisher","first-page":"4950","DOI":"10.1245\/s10434-020-08790-2","volume":"27","author":"SD Forsythe","year":"2020","unstructured":"Forsythe SD, Sasikumar S, Moaven O, Sivakumar H, Shen P, Levine EA, et al. Personalized Identification of Optimal HIPEC Perfusion Protocol in Patient-Derived Tumor Organoid Platform. Ann Surg Oncol. 2020;27(13):4950\u201360.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"3052_CR30","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.trecan.2019.12.008","volume":"6","author":"W Cleelen","year":"2020","unstructured":"Cleelen W, Ramsay RG, Narasimhan V, Heriot AG, De Wever O. Targeting the Tumor Microenvironment in Colorectal Peritoneal Metastases. Trends in Cancer. 2020;6(3):236\u201346.","journal-title":"Trends in Cancer."},{"issue":"1","key":"3052_CR31","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1186\/s12885-022-09572-7","volume":"22","author":"F Pereira","year":"2022","unstructured":"Pereira F, Serrano A, Manzanedo I, P\u00e9rez-Viejo E, Gonz\u00e1lez-Moreno S, Gonz\u00e1lez-Bay\u00f3n L, et al. GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases. BMC Cancer. 2022;22(1):536.","journal-title":"BMC Cancer"},{"issue":"7","key":"3052_CR32","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s11912-022-01275-3","volume":"24","author":"CE Guerra-Londono","year":"2022","unstructured":"Guerra-Londono CE, Tarazona CG, S\u00e1nchez-Monroy JA, Heppell O, Guerra-Londono JJ, Shah R. The Role of Hyperthermia in the Treatment of Peritoneal Surface Malignancies. Curr Oncol Rep. 2022;24(7):875\u201387.","journal-title":"Curr Oncol Rep."},{"issue":"12","key":"3052_CR33","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1016\/j.ejso.2018.07.003","volume":"44","author":"M Bushati","year":"2018","unstructured":"Bushati M, Rovers KP, Sommariva A, Sugarbaker PH, Morris DL, Yonemura Y, et al. The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol. 2018;44(12):1942\u20138.","journal-title":"Eur J Surg Oncol"},{"key":"3052_CR34","doi-asserted-by":"publisher","first-page":"715119","DOI":"10.3389\/fsurg.2021.715119","volume":"8","author":"F Santullo","year":"2021","unstructured":"Santullo F, Pacelli F, Abatini C, Attalla El, Halabieh M, Fortunato G, Lodoli C, et al. Cytoreduction and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendiceal origin: a single center experience. Front Surg. 2021;8:715119.","journal-title":"Front Surg"},{"issue":"8","key":"3052_CR35","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.3390\/cells9081775","volume":"9","author":"R Helderman","year":"2020","unstructured":"Helderman R, L\u00f6ke DR, Verhoeff J, Rodermond HM, van Bochove GGW, Boon M, et al. The Temperature-Dependent Effectiveness of Platinum-Based Drugs Mitomycin-C and 5-FU during Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Cell Lines. Cells. 2020;9(8):1775.","journal-title":"Cells."},{"issue":"2","key":"3052_CR36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s002800050721","volume":"41","author":"P Jacquet","year":"1998","unstructured":"Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol. 1998;41(2):147\u201354.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"3052_CR37","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1208\/s12248-020-00489-2","volume":"22","author":"F Xie","year":"2020","unstructured":"Xie F, Van Bocxlaer J, Colin P, Carlier C, Van Kerschaver O, Weerts J, et al. PKPD Modeling and Dosing Considerations in Advanced Ovarian Cancer Patients Treated with Cisplatin-Based Intraoperative Intraperitoneal Chemotherapy. AAPS J. 2020;22(5):96.","journal-title":"AAPS J"},{"issue":"1","key":"3052_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/02656730902747919","volume":"25","author":"WC Dewey","year":"2009","unstructured":"Dewey WC. Arrhenius relationships from the molecule and cell to the clinic. Int J Hyperth. 2009;25(1):3\u201320.","journal-title":"Int J Hyperth"},{"issue":"1","key":"3052_CR39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13046-022-02591-z","volume":"42","author":"F Papaccio","year":"2023","unstructured":"Papaccio F, Garc\u00eda-Mico B, Gimeno-Valiente F, Cabeza-Segura M, Gambardella V, Guti\u00e9rrez-Bravo MF, et al. Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction. J Exp Clin Cancer Res. 2023;42(1):8.","journal-title":"J Exp Clin Cancer Res."},{"key":"3052_CR40","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41568-018-0038-z","volume":"18","author":"H Hamidi","year":"2018","unstructured":"Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer. 2018;18:533\u201348.","journal-title":"Nat Rev Cancer"},{"key":"3052_CR41","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nrc.2017.118","volume":"18","author":"T Brabletz","year":"2018","unstructured":"Brabletz T, Kalluri R, Nieto AM, Weinberg RA. EMT in cancer. Nat Rev Cancer. 2018;18:128\u201334.","journal-title":"Nat Rev Cancer"},{"key":"3052_CR42","doi-asserted-by":"publisher","first-page":"7692","DOI":"10.3748\/wjg.v22.i34.7692","volume":"22","author":"L Lemoine","year":"2016","unstructured":"Lemoine L, Sugarbaker P, Van der Speeten K. Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum. World J Gastroenterol. 2016;22:7692\u2013707.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"3052_CR43","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41568-020-00329-7","volume":"21","author":"TR Cox","year":"2021","unstructured":"Cox TR. The matrix in cancer. Nat Rev Cancer. 2021;21(4):217\u201338.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"3052_CR44","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.3390\/cancers12071875","volume":"12","author":"E Janssen","year":"2020","unstructured":"Janssen E, Subtil B, de la Jara OF, Verheul HMW, Tauriello DVF. Combinatorial immunotherapies for metastatic colorectal cancer. Cancers (Basel). 2020;12(7):1875.","journal-title":"Cancers (Basel)"},{"issue":"7804","key":"3052_CR45","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41586-020-2166-3","volume":"580","author":"M Roulis","year":"2020","unstructured":"Roulis M, Kaklamanos A, Schernthanner M, Bielecki P, Zhao J, Kaffe E, et al. Paracrine orchestration of intestinal tumorigenesis by a mesenchymal niche. Nature. 2020;580(7804):524\u20139.","journal-title":"Nature"},{"issue":"7","key":"3052_CR46","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41588-022-01088-x","volume":"54","author":"WR Becker","year":"2022","unstructured":"Becker WR, Nevins SA, Chen DC, Chiu R, Horning AM, Guha TK, et al. Single-cell analyses define a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer. Nat Genet. 2022;54(7):985\u201395.","journal-title":"Nat Genet"},{"issue":"7","key":"3052_CR47","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41416-020-0973-9","volume":"123","author":"J Pape","year":"2020","unstructured":"Pape J, Magdeldin T, Stamati K, Nyga A, Loizidou M, Emberton M, et al. Cancer-associated fibroblasts mediate cancer progression and remodel the tumortumoroid stroma. Br J cancer. 2020;123(7):1178\u201390.","journal-title":"Br J cancer"},{"issue":"10","key":"3052_CR48","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.3390\/cancers12102861","volume":"12","author":"P Hurtado","year":"2020","unstructured":"Hurtado P, Martinez-Pena I, Pineiro R. Dangerous liaisons: circulating tumor cells (CTCs) and cancer-associated fibroblasts (CAFs). Cancers (Basel). 2020;12(10):2861.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"3052_CR49","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.cell.2018.01.009","volume":"172","author":"S Su","year":"2018","unstructured":"Su S, Chen J, Yao H, Liu J, Yu S, Lao L, et al. CD10(+)GPR77(+) cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell. 2018;172(4):841\u201356.e16.","journal-title":"Cell"},{"issue":"6","key":"3052_CR50","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.3390\/cancers12061393","volume":"12","author":"CM Garvey","year":"2020","unstructured":"Garvey CM, Lau R, Sanchez A, Sun RX, Fong EJ, Doche ME, et al. Anti-EGFR therapy induces EGF secretion by cancer-associated fibroblasts to confer colorectal cancer chemoresistance. Cancers (Basel). 2020;12(6):1393.","journal-title":"Cancers (Basel)"},{"key":"3052_CR51","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.coi.2020.03.004","volume":"64","author":"R Barrett","year":"2020","unstructured":"Barrett R, Pure E. Cancer-associated fibroblasts: key determinants of tumor immunity and immunotherapy. Curr Opin Immunol. 2020;64:80\u20137.","journal-title":"Curr Opin Immunol"},{"key":"3052_CR52","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3389\/fimmu.2019.01835","volume":"10","author":"L Monteran","year":"2019","unstructured":"Monteran L, Erez N. The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front Immunol. 2019;10:1835.","journal-title":"Front Immunol"},{"issue":"9","key":"3052_CR53","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","volume":"10","author":"Y Kieffer","year":"2020","unstructured":"Kieffer Y, Hocine HR, Gentric G, Pelon F, Bernard C, Bourachot B, et al. Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 2020;10(9):1330\u201351.","journal-title":"Cancer Discov"},{"issue":"6","key":"3052_CR54","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ccell.2022.04.011","volume":"40","author":"H Huang","year":"2022","unstructured":"Huang H, Wang Z, Zhang Y, Pradhan RN, Ganguly D, Chandra R, et al. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell. 2022;40(6):656\u201373.e7.","journal-title":"Cancer Cell"},{"issue":"12","key":"3052_CR55","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.tibtech.2020.04.006","volume":"38","author":"LP Ferreira","year":"2020","unstructured":"Ferreira LP, Gaspar VM, Mano JF. Decellularized Extracellular Matrix for Bioengineering Physiomimetic 3D in Vitro Tumor Models. Trends Biotechnol. 2020;38(12):1397\u2013414.","journal-title":"Trends Biotechnol"},{"issue":"11","key":"3052_CR56","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.3390\/jpm12111939","volume":"12","author":"F Papaccio","year":"2022","unstructured":"Papaccio F, Cabeza-Segura M, Garcia-Mic\u00f2 B, Tarazona N, Roda D, Castillo J, et al. Will Organoids Fill the Gap towards Functional Precision Medicine?. J Pers Med. 2022;12(11):1939.","journal-title":"J Pers Med."}],"updated-by":[{"DOI":"10.1186\/s13046-024-03092-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000}}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03052-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-024-03052-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03052-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T03:05:46Z","timestamp":1718161546000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-024-03052-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3052"],"URL":"https:\/\/doi.org\/10.1186\/s13046-024-03052-5","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]},"assertion":[{"value":"4 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13046-024-03092-x","URL":"https:\/\/doi.org\/10.1186\/s13046-024-03092-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocols followed all relevant ethical regulations in accordance with the Declaration of Helsinki principles (2009). Fresh tumour tissues were obtained within two institutional review board-approved, ethics committee-approved protocols: 134\/13, 149\/19, and 06\/21. All patients signed informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patients whose cases are presented signed the trial 134\/13,149\/19, and\/or 06\/21 consent forms. All the authors declare their consent for the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}